JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.

Mehta, Puja; Ciurtin, Coziana; Scully, Marie; Levi, Marcel; Chambers, Rachel C

Mehta, Puja; Ciurtin, Coziana; Scully, Marie; Levi, Marcel; Chambers, Rachel C.

Mehta P; Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.
Ciurtin C; Dept of Rheumatology, University College London (UCL) Centre for Adolescent Rheumatology, London, UK.
Scully M; Dept of Rheumatology, University College London (UCL) Centre for Adolescent Rheumatology, London, UK.
Levi M; Dept of Haematology, University College London Hospital (UCLH), London, UK.
Chambers RC; Dept of Medicine, University College London Hospitals (UCLH), London, UK.

Eur Respir J ; 56(3)2020 09.

Article in English | MEDLINE | ID: covidwho-635477

Subject(s)

Coronavirus Infections; Janus Kinase Inhibitors; Pandemics; Pneumonia, Viral; Pulmonary Embolism; Betacoronavirus; COVID-19; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Pulmonary Embolism / Coronavirus Infections / Pandemics / Janus Kinase Inhibitors Type of study: Prognostic study Limits: Humans Language: English Year: 2020 Document Type: Article Affiliation country: 13993003.01919-2020

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google